Skip to content

Clinical trials

Agnosia trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Agnosia Phase: Not applicable Country / region: United States Clear all

300 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20022
20035
20042
20054
20067
20077
200810
20098
20106
20115
201212
201311
201412
201520
201616
20179
201815
201916
202017
202123
202211
202314
20247
202526
202629

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed166
Recruiting41
Terminated28
Withdrawn21
Not yet recruiting18
Unknown status17
Active, not recruiting8
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The University of Texas Health Science Center, Houston6
VA Office of Research and Development6
Wake Forest University Health Sciences6
Duke University5
Johns Hopkins University5
Massachusetts General Hospital5
The Cleveland Clinic5
University of California, Los Angeles5
University of Colorado, Denver5
University of Michigan5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Agnosia300
Pain97
Chronic Pain34
Postoperative Pain27
Acute Pain20
Anxiety Disorders11
Neoplasms8
Low Back Pain7
Musculoskeletal Pain7
Opioid-Related Disorders7

Trials

Showing 1 to 25 of 300. Each trial links to its page on Pharma Observatory.

200 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.